1. Home
  2. AREB vs PHIO Comparison

AREB vs PHIO Comparison

Compare AREB & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AREB

American Rebel Holdings Inc.

HOLD

Current Price

$0.06

Market Cap

5.5M

Sector

Industrials

ML Signal

HOLD

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$1.22

Market Cap

14.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AREB
PHIO
Founded
2014
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Plastic Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5M
14.6M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
AREB
PHIO
Price
$0.06
$1.22
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$10.67
AVG Volume (30 Days)
3.6M
447.5K
Earning Date
11-10-2025
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$0.81
52 Week High
$28.00
$4.19

Technical Indicators

Market Signals
Indicator
AREB
PHIO
Relative Strength Index (RSI) 32.85 52.26
Support Level N/A $1.01
Resistance Level $1.34 $1.21
Average True Range (ATR) 0.02 0.08
MACD 0.01 0.00
Stochastic Oscillator 0.79 71.15

Price Performance

Historical Comparison
AREB
PHIO

About AREB American Rebel Holdings Inc.

American Rebel Holdings Inc develops self-defense, safe storage, and patriotic product areas using a wholesale distribution network, utilizing personal appearances, musical venue performances, as well as e-commerce and television. It designs, manufactures, and markets concealed carry products. It offers products ranging in Backpacks, jackets, coats, and Others. The Company views its operations and manages its business as one operating segment engaged in patriotic goods, comprised of safes, soft goods, and beer.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: